Antiviral Drug News and Research

RSS

Study aims to develop broad-spectrum antivirals against SARS-CoV-2 via drug repurposing strategies

This study aims to determine which FDA-approved compound(s) can be repurposed as a broad-spectrum antiviral drug(s) against SARS-CoV-2 and variants.

24 Nov 2022

NIAID awards more than $12 million for the development of antiviral therapies

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, recently awarded more than $12 million to three institutions for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential.

21 Nov 2022

Evaluating differences in viral and symptom rebounds between Paxlovid-treated and untreated COVID-19 patients

Researchers evaluated differences in viral and symptom rebounds between Paxlovid-treated and untreated coronavirus disease 2019 (COVID-19) patients.

17 Nov 2022

Study concludes monkeypox virus is readily detected by qPCR using three clinically validated assays

Researchers validated monkeypox virus (MPXV) quantitative polymerase chain reaction (qPCR) assays.

17 Nov 2022

Exploring antiviral drug combinations for SARS-CoV-2 suppression

Researchers assessed the impact of drug combinations on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suppression.

14 Nov 2022

Researchers use brain organoids to show how SARS-CoV-2 virus infects cortical neurons

Using human brain organoids, an international team of researchers, led by scientists at University of California San Diego School of Medicine and Sanford Consortium, has shown how the SARS-CoV-2 virus that causes COVID-19 infects cortical neurons and specifically destroys their synapses -; the connections between brain cells that allow them to communicate with each other.

3 Nov 2022

Viral shedding rate declines rapidly during the first year among people with HSV-1 genital infections

People with a genital infection of the herpes simplex virus type 1 (HSV-1), which usually causes cold sores, frequently shed the virus in the first months after infection, raising the risk that they might spread the virus to sexual partners during this time.

24 Oct 2022

Exploring molecular docking and molecular dynamics simulations as advanced tools for novel antiviral drug discovery

Researchers presented an overview of factors influencing emerging infectious diseases. They also highlighted the importance of molecular dynamic (MD) simulations and molecular docking (MDO) analysis for combating these diseases.

17 Oct 2022

Inhalation therapeutics against COVID-19

A recent study published in the Pulmonary Pharmacology & Therapeutics journal described different inhalation therapeutic agents for treating respiratory viral infections like coronavirus disease 2019 (COVID-19).

17 Oct 2022

Transition in the management of COVID-19

A review of the current approaches to managing COVID-19, including diagnostic, therapeutic, and preventive measures.

16 Oct 2022

Clinical trial to evaluate antiviral drug for monkeypox begins in the Democratic Republic of the Congo

A clinical trial to evaluate the antiviral drug tecovirimat, also known as TPOXX, in adults and children with monkeypox has begun in the Democratic Republic of the Congo (DRC).

12 Oct 2022

Researchers explore COVID-19 test-and-treat model computation with orally administered antiviral agents

In a new study, researchers used an oral antiviral agent-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test- and- treat (TT) model for coronavirus disease 2019 (COVID-19) mitigation in low-income countries (LICs).

10 Oct 2022

Structural analysis of monkeypox virus H1 dual phosphatase as a pan-poxvirus target

In a new study, researchers determined the 1.8-Å resolution crystal structure of the H1 dual specific phosphatase (DSP) of monkeypox virus (MPXV) that is crucial for viral replication, making it an attractive antiviral target.

5 Oct 2022

Small antiviral molecules termed assembly modulators show therapeutic efficacy against cancer

In a new study, researchers evaluated the anti-cancer therapeutic efficacy of two structurally-unrelated small molecules, PAV-617 and PAV-951.

4 Oct 2022

What are the challenges of COVID-19 vaccination and herd immunity?

A new study reviewed the challenges of coronavirus disease 2019 (COVID-19) vaccination and herd immunity.

4 Oct 2022

Study finds remdesivir-resistant version of COVID-19 in renal transplant recipients

Recent studies have shown that patients with weakened immune systems—which enables the virus that causes COVID-19 to remain longer in the body, copy itself, and continually change—may enable the development of new, slightly different versions of the virus (variants).

26 Sep 2022

Viruses exploit ability to sense the environment to maximize their infective yield

New UMBC-led research in Frontiers in Microbiology suggests that viruses are using information from their environment to "decide" when to sit tight inside their hosts and when to multiply and burst out, killing the host cell. The work has implications for antiviral drug development.

23 Sep 2022

Antibody drugs are not recommended for patients with covid-19, say WHO experts

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with covid-19, says a WHO Guideline Development Group of international experts in The BMJ today.

16 Sep 2022

Disrupting a virus’s genome packaging can halt replication, study finds

Like savvy international travelers, viruses know exactly how to pack. With the genetic instructions for the next generation folded just so, snuggled into a custom-made outer covering studded with cell-grabbing proteins, these tiny invaders quest for new digs on the reg.

30 Aug 2022

Relapse of COVID-19 symptoms and SARS-CoV-2 viral load following nirmatrelvir/ritonavir treatment

Researchers reported rapid relapse of COVID-19 symptoms following the administration of nirmatrelvir/ritonavir in adults.